A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles.

J Med Chem

Pfizer Central Research, Pfizer, Inc., Groton, Connecticut 06340.

Published: February 1989

Antagonism of mercaptopropionic acid (MPA) induced convulsions, reflecting a GABAergic mechanism, was observed in a series of 1-aryl-3-(aminoalkylidene)oxindoles. Optimal MPA antagonism was associated with 3-halo, 3-alkyl, and/or 4-alkoxy substituents in the pendant aryl ring and with (dimethylamino)methylene, 1-(dimethylamino)-ethylidene and N-methyl-2-pyrrolidinylidene side chains. The precise mechanism of action of these agents is unclear at this time; however, they are not GABA mimics and they do not affect GABA levels. Like other GABAergic agents, these compounds are potent enhancers of benzodiazepine binding and they antagonize cyclic GMP elevations induced by isoniazid. Compounds from this series may therefore have potential therapeutic utility as anticonvulsants or anxiolytics.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm00122a025DOI Listing

Publication Analysis

Top Keywords

novel class
4
class "gabaergic"
4
"gabaergic" agents
4
agents 1-aryl-3-aminoalkylideneoxindoles
4
1-aryl-3-aminoalkylideneoxindoles antagonism
4
antagonism mercaptopropionic
4
mercaptopropionic acid
4
acid mpa
4
mpa induced
4
induced convulsions
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!